Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of PegiHep for COVID-19

Trial Profile

A phase 3 study of PegiHep for COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Zydus Cadila
  • Most Recent Events

    • 05 Apr 2021 According to a Zydus Cadila media release, the company has applied for an approval for additional indication with the DCGI for the use of PegIFN in the treatment of COVID 19 with this positive interim results.
    • 05 Apr 2021 According to a Zydus Cadila media release, detailed results will be published in a peer-reviewed scientific journal.
    • 05 Apr 2021 Interim results published in the Zydus Cadila Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top